(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Pareteum Corporation, Hostess Brands, and NeuroMetrix.

Rank Financial Asset Price Change Updated (EST)
1 Pareteum Corporation (TEUM) 0.03 50% 2022-01-18 03:47:13
2 Hostess Brands (TWNKW) 3.20 41.59% 2022-01-18 07:17:05
3 NeuroMetrix (NURO) 6.46 31.3% 2022-01-18 13:36:10
4 Activision Blizzard (ATVI) 82.03 25.44% 2022-01-18 13:35:26
5 Tuscan Holdings Corp. II (THCAW) 0.44 16.95% 2022-01-18 04:23:13
6 Vistas Media Acquisition Company (VMACW) 0.46 13.72% 2022-01-18 11:49:15
7 Turning Point Therapeutics (TPTX) 38.34 9.48% 2022-01-18 05:15:05
8 Stable Road Acquisition Corp. (SRACU) 12.20 8.35% 2022-01-17 22:43:14
9 Verb Technology Company (VERBW) 0.65 8.25% 2022-01-18 09:14:06
10 Verb Technology Company (VERB) 1.37 7.03% 2022-01-18 09:13:06

The three most active and biggest losers today are Arcturus Therapeutics, ToughBuilt Industries, and BioNTech SE.

Rank Financial Asset Price Change Updated (EST)
1 Arcturus Therapeutics (ARCT) 27.21 -18.73% 2022-01-18 16:00:44
2 ToughBuilt Industries (TBLTW) 0.11 -15.34% 2022-01-18 03:09:06
3 BioNTech SE (BNTX) 168.90 -13.83% 2022-01-18 13:36:58
4 Unilever (UL) 47.26 -12.96% 2022-01-18 13:47:43
5 Novavax (NVAX) 98.44 -11.17% 2022-01-18 16:13:24
6 10x Genomics (TXG) 92.69 -10.87% 2022-01-18 16:03:43
7 Pacific Biosciences of California (PACB) 11.12 -10.54% 2022-01-18 16:13:35
8 Amicus Therapeutics (FOLD) 9.45 -10.26% 2022-01-18 16:11:25
9 SmileDirectClub (SDC) 2.02 -10.22% 2022-01-18 16:03:13
10 Inovio Pharmaceuticals (INO) 4.28 -9.89% 2022-01-18 15:57:06

Most Active Winners today

1. Pareteum Corporation (TEUM) – 50%

NASDAQ ended the session with Pareteum Corporation jumping 50% to $0.03 on Tuesday while NASDAQ fell 2.6% to $14,506.90.

Volume

Today’s last reported volume for Pareteum Corporation is 288256 which is 87.85% above its average volume of 153450.

Pareteum Corporation’s last close was $0.03, 95.28% under its 52-week high of $0.64.

Pareteum Corporation’s Revenue

Year-on-year quarterly revenue growth declined by 22.9%, now sitting on 65.05M for the twelve trailing months.

Pareteum Corporation’s Stock Yearly Top and Bottom Value

Pareteum Corporation’s stock is valued at $0.03 at 16:32 EST, way under its 52-week high of $0.64 and way higher than its 52-week low of $0.00.

Pareteum Corporation’s Moving Average

Pareteum Corporation’s value is way under its 50-day moving average of $0.03 and way under its 200-day moving average of $0.21.

More news about Pareteum Corporation.

2. Hostess Brands (TWNKW) – 41.59%

NASDAQ ended the session with Hostess Brands rising 41.59% to $3.20 on Tuesday, after three sequential sessions in a row of losses. NASDAQ dropped 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around down trend exchanging session today.

Volume

Today’s last reported volume for Hostess Brands is 29718 which is 70.4% below its average volume of 100427.

Hostess Brands’s last close was $3.20, 20.36% below its 52-week high of $4.02.

Hostess Brands’s Stock Yearly Top and Bottom Value

Hostess Brands’s stock is valued at $3.20 at 16:32 EST, way below its 52-week high of $4.02 and way higher than its 52-week low of $1.12.

Hostess Brands’s Moving Average

Hostess Brands’s value is below its 50-day moving average of $3.36 and way above its 200-day moving average of $2.53.

More news about Hostess Brands.

3. NeuroMetrix (NURO) – 31.3%

NASDAQ ended the session with NeuroMetrix jumping 31.3% to $6.46 on Tuesday, following the last session’s upward trend. NASDAQ fell 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for NeuroMetrix is 53843500 which is 16063.5% above its average volume of 333117.

NeuroMetrix’s last close was $4.92, 87.3% under its 52-week high of $38.75.

NeuroMetrix’s Revenue

Year-on-year quarterly revenue growth declined by 0.8%, now sitting on 7.36M for the twelve trailing months.

NeuroMetrix’s Stock Yearly Top and Bottom Value

NeuroMetrix’s stock is valued at $6.46 at 16:32 EST, way below its 52-week high of $38.75 and way above its 52-week low of $1.90.

NeuroMetrix’s Moving Average

NeuroMetrix’s value is way under its 50-day moving average of $8.84 and below its 200-day moving average of $6.85.

More news about NeuroMetrix.

4. Activision Blizzard (ATVI) – 25.44%

NASDAQ ended the session with Activision Blizzard jumping 25.44% to $82.03 on Tuesday while NASDAQ slid 2.6% to $14,506.90.

Volume

Today’s last reported volume for Activision Blizzard is 92300100 which is 638.84% above its average volume of 12492500.

Activision Blizzard’s last close was $65.39, 37.44% under its 52-week high of $104.53.

News about Activision Blizzard today

  • Update: Microsoft to acquire activision blizzard in all-cash deal valued at $68.7 billion to mark its biggest-ever deal. According to today’s article on MarketWatch, "Microsoft Corp. said Tuesday it has reached an agreement to acquire Activision Blizzard Inc. in an all-cash deal valued at $68.7 billion that will be the biggest ever by the software giant. "
  • Here's how much $100 invested in activision blizzard 15 years ago would be worth today. According to today’s article on Benzinga, "Buying $100 In ATVI: 15 years ago, an investor could have purchased 11.40 shares of Activision Blizzard at the time with $100. ", "If you had invested $100 in Activision Blizzard you would have approximately $930.48 today."
  • Activision blizzard (atvi) stock news and forecast: Microsoft (msft) buys activision, key info. According to today’s article on FXStreet, "The Wall Street Journal appears to have been the first one to break the news on Tuesday of the mega-merger between Microsoft (MSFT) and Activision Blizzard (ATVI). "
  • Mid-day market update: nasdaq tumbles 250 points; activision blizzard shares jump. According to today’s article on Benzinga, "Microsoft on Tuesday announced that it plans to acquire game developer and interactive entertainment content publisher Activision Blizzard for $95 per share in an all-cash transaction valued at $68.7 billion."
  • Shareholder notice: brodsky & smith announces an investigation of activision blizzard inc. (nasdaq – atvi). According to today’s article on Benzinga, "BALA CYNWYD, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) — Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Activision Blizzard Inc. ("Activision" or the "Company") (Nasdaq – ATVI) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by Microsoft Corp. (NASDAQ:MSFT). ", "Under the terms of the agreement, Microsoft will acquire Activision Blizzard for $95.00 per share, in an all-cash transaction valued at $68.7 billion, inclusive of Activision Blizzard’s net cash."

Activision Blizzard’s Sales

Activision Blizzard’s sales growth is 11.2% for the ongoing quarter and a decline by 3.7% for the next. The company’s growth estimates for the ongoing quarter is a negative 1.4% and positive 14% for the next.

Activision Blizzard’s Revenue

Year-on-year quarterly revenue growth grew by 18.8%, now sitting on 8.94B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Activision Blizzard’s stock is considered to be oversold (<=20).

Activision Blizzard’s Stock Yearly Top and Bottom Value

Activision Blizzard’s stock is valued at $82.03 at 16:32 EST, way below its 52-week high of $104.53 and way above its 52-week low of $59.78.

Activision Blizzard’s Moving Average

Activision Blizzard’s value is way higher than its 50-day moving average of $73.15 and below its 200-day moving average of $86.67.

More news about Activision Blizzard.

5. Tuscan Holdings Corp. II (THCAW) – 16.95%

NASDAQ ended the session with Tuscan Holdings Corp. II rising 16.95% to $0.44 on Tuesday, after five sequential sessions in a row of losses. NASDAQ slid 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around negative trend exchanging session today.

Tuscan Holdings Corp. II’s last close was $0.44, 0.02% below its 52-week high of $0.44.

Tuscan Holdings Corp. II’s Stock Yearly Top and Bottom Value

Tuscan Holdings Corp. II’s stock is valued at $0.44 at 16:32 EST, under its 52-week high of $0.44 and way higher than its 52-week low of $0.38.

More news about Tuscan Holdings Corp. II.

6. Vistas Media Acquisition Company (VMACW) – 13.72%

NASDAQ ended the session with Vistas Media Acquisition Company rising 13.72% to $0.46 on Tuesday, after five successive sessions in a row of losses. NASDAQ fell 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around negative trend trading session today.

Vistas Media Acquisition Company’s last close was $0.68, 30.75% higher than its 52-week high of $0.52.

Vistas Media Acquisition Company’s Stock Yearly Top and Bottom Value

Vistas Media Acquisition Company’s stock is valued at $0.46 at 16:32 EST, way below its 52-week high of $0.52 and way above its 52-week low of $0.41.

More news about Vistas Media Acquisition Company.

7. Turning Point Therapeutics (TPTX) – 9.48%

NASDAQ ended the session with Turning Point Therapeutics jumping 9.48% to $38.34 on Tuesday while NASDAQ fell 2.6% to $14,506.90.

Volume

Today’s last reported volume for Turning Point Therapeutics is 764470 which is 59.13% above its average volume of 480385.

Turning Point Therapeutics’s last close was $38.34, 72.87% below its 52-week high of $141.30.

The company’s growth estimates for the ongoing quarter and the next is a negative 36.3% and a negative 80.8%, respectively.

Turning Point Therapeutics’s Revenue

Year-on-year quarterly revenue growth declined by 98.2%, now sitting on 30.83M for the twelve trailing months.

Turning Point Therapeutics’s Stock Yearly Top and Bottom Value

Turning Point Therapeutics’s stock is valued at $38.34 at 16:32 EST, way under its 52-week high of $141.30 and way higher than its 52-week low of $34.16.

Turning Point Therapeutics’s Moving Average

Turning Point Therapeutics’s value is way under its 50-day moving average of $42.69 and way below its 200-day moving average of $62.07.

More news about Turning Point Therapeutics.

8. Stable Road Acquisition Corp. (SRACU) – 8.35%

NASDAQ ended the session with Stable Road Acquisition Corp. rising 8.35% to $12.20 on Tuesday while NASDAQ dropped 2.6% to $14,506.90.

Volume

Today’s last reported volume for Stable Road Acquisition Corp. is 1893 which is 4.58% above its average volume of 1810.

Stable Road Acquisition Corp.’s last close was $12.20, 65.14% below its 52-week high of $35.00.

Stable Road Acquisition Corp.’s Stock Yearly Top and Bottom Value

Stable Road Acquisition Corp.’s stock is valued at $12.20 at 16:32 EST, way below its 52-week high of $35.00 and way above its 52-week low of $9.78.

Stable Road Acquisition Corp.’s Moving Average

Stable Road Acquisition Corp.’s value is above its 50-day moving average of $12.08 and way below its 200-day moving average of $15.74.

More news about Stable Road Acquisition Corp..

9. Verb Technology Company (VERBW) – 8.25%

NASDAQ ended the session with Verb Technology Company jumping 8.25% to $0.65 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ slid 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around bearish trend trading session today.

Verb Technology Company’s last close was $0.65, 0.03% under its 52-week high of $0.65.

Verb Technology Company’s Stock Yearly Top and Bottom Value

Verb Technology Company’s stock is valued at $0.65 at 16:32 EST, below its 52-week low of $0.63.

More news about Verb Technology Company.

10. Verb Technology Company (VERB) – 7.03%

NASDAQ ended the session with Verb Technology Company rising 7.03% to $1.37 on Tuesday, following the last session’s upward trend. NASDAQ dropped 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for Verb Technology Company is 846454 which is 28.72% below its average volume of 1187660.

Verb Technology Company’s last close was $1.37, 65.49% under its 52-week high of $3.97.

Verb Technology Company’s Sales

Verb Technology Company’s sales growth is 56.3% for the present quarter and 11.7% for the next. The company’s growth estimates for the ongoing quarter and the next is 62.1% and 43.8%, respectively.

Verb Technology Company’s Revenue

Year-on-year quarterly revenue growth grew by 1.4%, now sitting on 9.92M for the twelve trailing months.

Verb Technology Company’s Stock Yearly Top and Bottom Value

Verb Technology Company’s stock is valued at $1.37 at 16:32 EST, way below its 52-week high of $3.97 and way above its 52-week low of $0.92.

Verb Technology Company’s Moving Average

Verb Technology Company’s value is below its 50-day moving average of $1.52 and way under its 200-day moving average of $1.69.

More news about Verb Technology Company.

Most Active Losers Today

1. Arcturus Therapeutics (ARCT) – -18.73%

NASDAQ ended the session with Arcturus Therapeutics dropping 18.73% to $27.21 on Tuesday, following the last session’s upward trend. NASDAQ fell 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around bearish trend exchanging session today.

Volume

Today’s last reported volume for Arcturus Therapeutics is 798224 which is 34.94% above its average volume of 591522.

Arcturus Therapeutics’s last close was $33.48, 73% under its 52-week high of $124.00.

Arcturus Therapeutics’s Sales

Arcturus Therapeutics’s sales growth is 625.3% for the present quarter and 1814.2% for the next. The company’s growth estimates for the present quarter is a negative 72.8% and positive 6.4% for the next.

Arcturus Therapeutics’s Revenue

Year-on-year quarterly revenue growth declined by 13.8%, now sitting on 8.7M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Arcturus Therapeutics’s stock is considered to be oversold (<=20).

Arcturus Therapeutics’s Stock Yearly Top and Bottom Value

Arcturus Therapeutics’s stock is valued at $27.21 at 16:32 EST, way below its 52-week high of $124.00 and above its 52-week low of $24.87.

Arcturus Therapeutics’s Moving Average

Arcturus Therapeutics’s value is way under its 50-day moving average of $40.67 and way under its 200-day moving average of $40.29.

More news about Arcturus Therapeutics.

2. ToughBuilt Industries (TBLTW) – -15.34%

NASDAQ ended the session with ToughBuilt Industries dropping 15.34% to $0.11 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ slid 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for ToughBuilt Industries is 32844 which is 152.02% above its average volume of 13032.

ToughBuilt Industries’s last close was $0.11, 87.79% below its 52-week high of $0.91.

ToughBuilt Industries’s Stock Yearly Top and Bottom Value

ToughBuilt Industries’s stock is valued at $0.11 at 16:32 EST, way under its 52-week high of $0.91 and above its 52-week low of $0.10.

ToughBuilt Industries’s Moving Average

ToughBuilt Industries’s value is way under its 50-day moving average of $0.15 and way under its 200-day moving average of $0.19.

More news about ToughBuilt Industries.

3. BioNTech SE (BNTX) – -13.83%

NASDAQ ended the session with BioNTech SE dropping 13.83% to $168.90 on Tuesday while NASDAQ fell 2.6% to $14,506.90.

Volume

Today’s last reported volume for BioNTech SE is 3207240 which is 4.6% below its average volume of 3362070.

BioNTech SE’s last close was $196.00, 57.76% below its 52-week high of $464.00.

The company’s growth estimates for the current quarter and the next is 1188.8% and 438%, respectively.

BioNTech SE’s Revenue

Year-on-year quarterly revenue growth grew by 12630.2%, now sitting on 7.77B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

BioNTech SE’s stock is considered to be overbought (>=80).

BioNTech SE’s Stock Yearly Top and Bottom Value

BioNTech SE’s stock is valued at $168.90 at 16:32 EST, way under its 52-week high of $464.00 and way higher than its 52-week low of $80.55.

BioNTech SE’s Moving Average

BioNTech SE’s value is way under its 50-day moving average of $269.93 and way below its 200-day moving average of $268.56.

More news about BioNTech SE.

4. Unilever (UL) – -12.96%

NYSE ended the session with Unilever sliding 12.96% to $47.26 on Tuesday while NYSE dropped 1.59% to $16,945.28.

Volume

Today’s last reported volume for Unilever is 27558900 which is 935.05% above its average volume of 2662550.

Unilever’s last close was $54.29, 13.89% below its 52-week high of $63.05.

Unilever’s Revenue

Year-on-year quarterly revenue growth grew by 0.3%, now sitting on 50.8B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Unilever’s stock is considered to be oversold (<=20).

Unilever’s Stock Yearly Top and Bottom Value

Unilever’s stock is valued at $47.26 at 16:32 EST, below its 52-week low of $51.98.

Unilever’s Moving Average

Unilever’s worth is way under its 50-day moving average of $53.48 and way under its 200-day moving average of $57.01.

Previous days news about Unilever

  • Unilever sets out ambition to expand in health products. According to The Wall Street Journal on Monday, 17 January, "The strategic update Monday came days after Unilever said it had approached GlaxoSmithKline PLC and Pfizer Inc. about buying their consumer-healthcare joint venture, GSK Consumer Healthcare. "
  • Glaxosmithkline shares soar after unilever bid for consumer health unit. According to MarketWatch on Monday, 17 January, "Shares of GlaxoSmithKline surged on Monday, while Unilever stock tumbled following a failed $68 billion bid by the latter to acquire the pharmaceutical giant’s consumer healthcare arm.", "Driving the FTSE 100 higher and at the top of the Stoxx Europe 600’s gainer’s list, was GlaxoSmithKline , up 5% after saying Saturday that it has rejected an unsolicited £50 billion ($68.4 billion) Unilever offer for the unit behind painkiller Advil and Sensodyne toothpaste that it jointly owns with Pfizer . "
  • Unilever makes approach for glaxo's consumer-healthcare business. According to The Wall Street Journal on Saturday, 15 January, "LONDON- Unilever PLC said it had approached GlaxoSmithKline PLC and Pfizer Inc. about an acquisition of their consumer-healthcare joint venture, a potential $68 billion deal that would reshape the consumer-products giant’s portfolio at a time when it is under pressure to accelerate growth."
  • Glaxosmithkline up 4% after failed $68b unilever bid for consumer health unit. According to MarketWatch on Monday, 17 January, "LONDON – The pharmaceutical giant GlaxoSmithKline said Saturday it has rejected an unsolicited 50 billion-pound ($68.4 billion) bid from Unilever for its consumer healthcare goods unit, a joint venture it controls in a partnership with Pfizer.", "The London-based company said in a and Unilever confirmed that an acquisition offer was made following a report in Britain’s Sunday Times. "
  • GSK spurns $68.4b bid from unilever for its consumer healthcare business, opts to spin-off the unit. According to Benzinga on Saturday, 15 January, "GlaxoSmithKline said in a statement Saturday that Unilever plc (NYSE: UL) tabled three unsolicited, conditional and non-binding proposals for acquiring its Consumer Healthcare business.", "The third proposal made on Dec. 20 sought to seal the deal for 50 billion pounds ($68.4 billion), comprising 41.7 billion pounds in cash and 8.3 billion pounds in Unilever shares."

More news about Unilever.

5. Novavax (NVAX) – -11.17%

NASDAQ ended the session with Novavax dropping 11.17% to $98.44 on Tuesday while NASDAQ dropped 2.6% to $14,506.90.

Volume

Today’s last reported volume for Novavax is 6477320 which is 3.45% above its average volume of 6261070.

Novavax’s last close was $110.82, 66.59% under its 52-week high of $331.68.

The company’s growth estimates for the ongoing quarter is a negative 21.8% and positive 213.7% for the next.

Novavax’s Revenue

Year-on-year quarterly revenue growth grew by 13.9%, now sitting on 1.2B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Novavax’s stock is considered to be overbought (>=80).

Novavax’s Stock Yearly Top and Bottom Value

Novavax’s stock is valued at $98.44 at 16:32 EST, under its 52-week low of $107.08.

Novavax’s Moving Average

Novavax’s worth is way under its 50-day moving average of $170.98 and way under its 200-day moving average of $193.54.

More news about Novavax.

6. 10x Genomics (TXG) – -10.87%

NASDAQ ended the session with 10x Genomics sliding 10.87% to $92.69 on Tuesday while NASDAQ dropped 2.6% to $14,506.90.

Volume

Today’s last reported volume for 10x Genomics is 1233460 which is 61.03% above its average volume of 765958.

10x Genomics’s last close was $104.00, 50.24% below its 52-week high of $208.99.

10x Genomics’s Sales

10x Genomics’s sales growth is 78.1% for the ongoing quarter and 33.2% for the next. The company’s growth estimates for the current quarter and the next is 70.8% and 97.2%, respectively.

10x Genomics’s Revenue

Year-on-year quarterly revenue growth grew by 170%, now sitting on 405.7M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

10x Genomics’s stock is considered to be overbought (>=80).

10x Genomics’s Stock Yearly Top and Bottom Value

10x Genomics’s stock is valued at $92.69 at 16:32 EST, way below its 52-week low of $128.15.

10x Genomics’s Moving Average

10x Genomics’s value is way below its 50-day moving average of $155.93 and way under its 200-day moving average of $170.12.

More news about 10x Genomics.

7. Pacific Biosciences of California (PACB) – -10.54%

NASDAQ ended the session with Pacific Biosciences of California dropping 10.54% to $11.12 on Tuesday, after five consecutive sessions in a row of losses. NASDAQ fell 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around bearish trend exchanging session today.

Volume

Today’s last reported volume for Pacific Biosciences of California is 5551330 which is 98.69% above its average volume of 2793850.

Pacific Biosciences of California’s last close was $12.43, 76.85% under its 52-week high of $53.69.

Pacific Biosciences of California’s Sales

Pacific Biosciences of California’s sales growth is 63.1% for the present quarter and 39.6% for the next. The company’s growth estimates for the current quarter and the next is a negative 50% and a negative 164.9%, respectively.

Pacific Biosciences of California’s Revenue

Year-on-year quarterly revenue growth grew by 79.2%, now sitting on 105.83M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be overbought (>=80).

Pacific Biosciences of California’s Stock Yearly Top and Bottom Value

Pacific Biosciences of California’s stock is valued at $11.12 at 16:32 EST, way below its 52-week low of $18.63.

Pacific Biosciences of California’s Moving Average

Pacific Biosciences of California’s value is way below its 50-day moving average of $25.02 and way below its 200-day moving average of $28.55.

More news about Pacific Biosciences of California.

8. Amicus Therapeutics (FOLD) – -10.26%

NASDAQ ended the session with Amicus Therapeutics falling 10.26% to $9.45 on Tuesday, following the last session’s upward trend. NASDAQ fell 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around down trend exchanging session today.

Volume

Today’s last reported volume for Amicus Therapeutics is 2235020 which is 11.41% below its average volume of 2523150.

Amicus Therapeutics’s last close was $10.53, 58.53% below its 52-week high of $25.39.

The company’s growth estimates for the current quarter and the next is 28% and 33.3%, respectively.

Amicus Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 24.2%, now sitting on 281.82M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Amicus Therapeutics’s stock is considered to be oversold (<=20).

Amicus Therapeutics’s Stock Yearly Top and Bottom Value

Amicus Therapeutics’s stock is valued at $9.45 at 16:32 EST, way below its 52-week high of $25.39 and higher than its 52-week low of $8.60.

Amicus Therapeutics’s Moving Average

Amicus Therapeutics’s value is way below its 50-day moving average of $11.12 and below its 200-day moving average of $10.29.

More news about Amicus Therapeutics.

9. SmileDirectClub (SDC) – -10.22%

NASDAQ ended the session with SmileDirectClub sliding 10.22% to $2.02 on Tuesday, after two consecutive sessions in a row of gains. NASDAQ fell 2.6% to $14,506.90, following the last session’s upward trend on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for SmileDirectClub is 9049080 which is 9.49% below its average volume of 9997930.

SmileDirectClub’s last close was $2.25, 86.01% below its 52-week high of $16.08.

SmileDirectClub’s Sales

SmileDirectClub’s sales growth is 25.6% for the present quarter and 10% for the next. The company’s growth estimates for the current quarter and the next is a negative 18.2% and a negative 33.3%, respectively.

SmileDirectClub’s Revenue

Year-on-year quarterly revenue growth grew by 62.7%, now sitting on 726.7M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

SmileDirectClub’s stock is considered to be oversold (<=20).

SmileDirectClub’s Stock Yearly Top and Bottom Value

SmileDirectClub’s stock is valued at $2.02 at 16:32 EST, way below its 52-week low of $2.54.

SmileDirectClub’s Moving Average

SmileDirectClub’s value is way below its 50-day moving average of $4.62 and way below its 200-day moving average of $7.31.

More news about SmileDirectClub.

10. Inovio Pharmaceuticals (INO) – -9.89%

NASDAQ ended the session with Inovio Pharmaceuticals dropping 9.89% to $4.28 on Tuesday while NASDAQ slid 2.6% to $14,506.90.

Volume

Today’s last reported volume for Inovio Pharmaceuticals is 4976850 which is 13.04% above its average volume of 4402730.

Inovio Pharmaceuticals’s last close was $4.75, 75% below its 52-week high of $19.00.

Inovio Pharmaceuticals’s Sales

Inovio Pharmaceuticals’s sales growth is 311% for the current quarter and 132.2% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 400% and a negative 121.4%, respectively.

Inovio Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 23.5%, now sitting on 6.52M for the twelve trailing months.

Inovio Pharmaceuticals’s Stock Yearly Top and Bottom Value

Inovio Pharmaceuticals’s stock is valued at $4.28 at 16:32 EST, way under its 52-week low of $5.75.

Inovio Pharmaceuticals’s Moving Average

Inovio Pharmaceuticals’s worth is way under its 50-day moving average of $6.91 and way below its 200-day moving average of $8.05.

More news about Inovio Pharmaceuticals.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here